Company intelligence / Profile preview

FBB Biomed

Iowa City, Iowa, United States

Ownership: Private
Development stage: Other

Overview

FBB Biomed is a biotechnology company specializing in the analysis of the ribonome to develop advanced diagnostics and therapeutics for complex diseases. The company leverages a proprietary platform to identify specific RNA fragments in blood that serve as highly accurate biomarkers for neurodegenerative conditions, including Alzheimer's and Parkinson's diseases. By focusing on the dark matter of the transcriptome, FBB Biomed aims to enable earlier diagnosis, monitor disease progression, and identify novel therapeutic targets. Their approach extends beyond neurology to include inflammatory and infectious diseases, such as Multiple Sclerosis and COVID-19.

Therapeutic areas: Infectious DiseasesNeurology
Modalities: RNA therapyMolecular diagnostic
Industry: Biotech

Beyond the preview

Go deeper on FBB Biomed.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on FBB Biomed.

Explore the full profile